

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



利君國際醫藥(控股)有限公司

Lijun International Pharmaceutical (Holding) Co., Ltd.

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2005)

ANNOUNCEMENT

This announcement is made pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (“Listing Rules”) and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong).

The board of directors (the “Board”) of Lijun International Pharmaceutical (Holding) Co., Ltd. (the Company”) has noted an announcement published by Sichuan Kelun Pharmaceutical Co., Ltd. today with the following contents being extracted:

“The Company intends to hold the shares of Lijun International being acquired this time for long-term investment purpose, which will complement the comparative advantage of both companies in order to achieve the target in increasing the sales efficiency, enhancing brand awareness, and expanding the market coverage of the products. Meanwhile, the advantages in the combination of the product brandings, types and specifications of both companies will facilitate formulation of reasonable bidding strategies, which in turn will reinforce and strengthen the competitive advantages in the bidding process for getting a higher bid acceptance rate. The product mix of the middle and high end soft-bag infusion solution and therapeutic infusion solution products of both companies will be further optimized and creating more outstanding competitive advantages. This will also facilitate the Company’s implementation of its strategies in global development.”

According to a sale and purchase agreement dated 4 June 2014, Sichuan Kelun Pharmaceutical Co., Ltd. through its wholly owned subsidiary Kelun International Development Co., Limited. acquired 145,300,000 shares of the Company at a price of HK\$2.75 each, represented approximately 4.96% of the total issued share capital of the Company.

Shareholders of the Company and potential investors are advised to exercise caution in dealing in the securities of the Company.

This announcement is made by the order of the Company. The Board collectively and individually accepts responsibility for the accuracy of this announcement.

By Order of the Board
Chan Ka Kit
Company Secretary

Hong Kong, 5 June 2014

As at the date of this announcement, the Board comprises Mr. Wu Qin, Mr. Qu Jiguang, Mr. Xie Yunfeng, Mr. Wang Xianjun and Mr. Duan Wei as executive Directors, and Mr. Wang Yibing, Mr. Leung Chong Shun and Mr. Chow Kwok Wai as independent non-executive Directors.